{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:58:02Z","timestamp":1791928682829,"version":"4.3.4"},"reference-count":33,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"7","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2018,6,19]]},"DOI":"10.1167\/iovs.18-24432","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T18:43:20Z","timestamp":1532112200000},"page":"3088","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome"],"prefix":"10.1167","volume":"59","author":[{"given":"Agne","family":"\u017diniauskaite","sequence":"first","affiliation":[{"name":"Experimentica Ltd., Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symantas","family":"Ragauskas","sequence":"additional","affiliation":[{"name":"Experimentica Ltd., Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni J.","family":"Hakkarainen","sequence":"additional","affiliation":[{"name":"Experimentica Ltd., Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cadmus C.","family":"Rich","sequence":"additional","affiliation":[{"name":"Inotek Pharmaceuticals Corp., Lexington, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Baumgartner","sequence":"additional","affiliation":[{"name":"Inotek Pharmaceuticals Corp., Lexington, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giedrius","family":"Kalesnykas","sequence":"additional","affiliation":[{"name":"Experimentica Ltd., Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Albers","sequence":"additional","affiliation":[{"name":"Inotek Pharmaceuticals Corp., Lexington, Massachusetts, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kaja","sequence":"additional","affiliation":[{"name":"Experimentica Ltd., Kuopio, Finland"},{"name":"Departments of Ophthalmology and Molecular Pharmacology and Therapeutics, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"i1552-5783-59-7-3088-b01","doi-asserted-by":"crossref","unstructured":"Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. Adv Exp Med Biol. 2002; 506: 989\u2013998.","DOI":"10.1007\/978-1-4615-0717-8_140"},{"key":"i1552-5783-59-7-3088-b02","doi-asserted-by":"crossref","unstructured":"Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009; 3: 405\u2013412.","DOI":"10.2147\/OPTH.S5555"},{"key":"i1552-5783-59-7-3088-b03","doi-asserted-by":"crossref","unstructured":"The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5: 93\u2013107.","DOI":"10.1016\/S1542-0124(12)70082-4"},{"key":"i1552-5783-59-7-3088-b04","doi-asserted-by":"crossref","unstructured":"Ames P, Galor A. Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence. Clin Investig (Lond). 2015; 5: 267\u2013285.","DOI":"10.4155\/cli.14.135"},{"key":"i1552-5783-59-7-3088-b05","doi-asserted-by":"crossref","unstructured":"American Medical Association. Lifitegrast (Xiidra) for dry eye disease. JAMA. 2017; 317: 1473\u20131474.","DOI":"10.1001\/jama.2016.12872"},{"key":"i1552-5783-59-7-3088-b06","doi-asserted-by":"crossref","unstructured":"Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017; 15: 575\u2013628.","DOI":"10.1016\/j.jtos.2017.05.006"},{"key":"i1552-5783-59-7-3088-b07","doi-asserted-by":"crossref","unstructured":"Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of Lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study. Cornea. 2016; 35: 741\u2013748.","DOI":"10.1097\/ICO.0000000000000803"},{"key":"i1552-5783-59-7-3088-b08","doi-asserted-by":"crossref","unstructured":"Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017; 15: 276\u2013283.","DOI":"10.1016\/j.jtos.2017.05.008"},{"key":"i1552-5783-59-7-3088-b09","doi-asserted-by":"crossref","unstructured":"Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017; 124: S4\u2013S13.","DOI":"10.1016\/j.ophtha.2017.07.010"},{"key":"i1552-5783-59-7-3088-b10","doi-asserted-by":"crossref","unstructured":"Drury AN, Szent-Gyorgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol. 1929; 68: 213\u2013237.","DOI":"10.1113\/jphysiol.1929.sp002608"},{"key":"i1552-5783-59-7-3088-b11","doi-asserted-by":"crossref","unstructured":"Jacobson KA, Kim SK, Costanzi S, Gao ZG. Purine receptors: GPCR structure and agonist design. Mol Interv. 2004; 4: 337\u2013347.","DOI":"10.1124\/mi.4.6.7"},{"key":"i1552-5783-59-7-3088-b12","doi-asserted-by":"crossref","unstructured":"Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J . International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001; 53: 527\u2013552.","DOI":"10.1016\/S0031-6997(24)01511-4"},{"key":"i1552-5783-59-7-3088-b13","doi-asserted-by":"crossref","unstructured":"Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 1986; 78: 760\u2013770.","DOI":"10.1172\/JCI112638"},{"key":"i1552-5783-59-7-3088-b14","doi-asserted-by":"crossref","unstructured":"Hasko G, Cronstein B. Regulation of inflammation by adenosine. Front Immunol. 2013; 4: 85.","DOI":"10.3389\/fimmu.2013.00085"},{"key":"i1552-5783-59-7-3088-b15","doi-asserted-by":"crossref","unstructured":"Nakav S, Chaimovitz C, Sufaro Y, et al. Anti-inflammatory preconditioning by agonists of adenosine A1 receptor. PLoS One. 2008; 3: e2107.","DOI":"10.1371\/journal.pone.0002107"},{"key":"i1552-5783-59-7-3088-b16","doi-asserted-by":"crossref","unstructured":"Lee HT, Gallos G, Nasr SH, Emala CW. A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol. 2004; 15: 102\u2013111.","DOI":"10.1097\/01.ASN.0000102474.68613.AE"},{"key":"i1552-5783-59-7-3088-b17","doi-asserted-by":"crossref","unstructured":"Tsutsui S, Schnermann J, Noorbakhsh F, et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci. 2004; 24: 1521\u20131529.","DOI":"10.1523\/JNEUROSCI.4271-03.2004"},{"key":"i1552-5783-59-7-3088-b18","doi-asserted-by":"crossref","unstructured":"Jacobson KA, Civan MM. Ocular purine receptors as drug targets in the eye. J Ocul Pharmacol Ther. 2016; 32: 534\u2013547.","DOI":"10.1089\/jop.2016.0090"},{"key":"i1552-5783-59-7-3088-b19","doi-asserted-by":"crossref","unstructured":"Laties A, Rich CC, Stoltz R, et al. A randomized phase 1 dose escalation study to evaluate safety, tolerability, and pharmacokinetics of Trabodenoson in healthy adult volunteers. J Ocul Pharmacol Ther. 2016; 32: 548\u2013554.","DOI":"10.1089\/jop.2015.0147"},{"key":"i1552-5783-59-7-3088-b20","doi-asserted-by":"crossref","unstructured":"Myers JS, Sall KN, DuBiner H, et al. A dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 weeks of twice-daily ocular Trabodenoson in adults with ocular hypertension or primary open-angle glaucoma. J Ocul Pharmacol Ther. 2016; 32: 555\u2013562.","DOI":"10.1089\/jop.2015.0148"},{"key":"i1552-5783-59-7-3088-b21","unstructured":"Dursun D, Wang M, Monroy D, et al. A mouse model of keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 2002; 43: 632\u2013638."},{"key":"i1552-5783-59-7-3088-b22","doi-asserted-by":"crossref","unstructured":"Nyunt AK, Ishida Y, Yu Y, Shimada S. Topical apolipoprotein A-1 may have a beneficial effect on the corneal epithelium in a mouse model of dry eye: a pilot study. Eye Contact Lens. 2008; 34: 287\u2013292.","DOI":"10.1097\/ICL.0b013e318184bdb6"},{"key":"i1552-5783-59-7-3088-b23","doi-asserted-by":"crossref","unstructured":"Yoon KC, De Paiva CS, Qi H, et al. Desiccating environmental stress exacerbates autoimmune lacrimal keratoconjunctivitis in non-obese diabetic mice. J Autoimmun. 2008; 30: 212\u2013221.","DOI":"10.1016\/j.jaut.2007.09.003"},{"key":"i1552-5783-59-7-3088-b24","doi-asserted-by":"crossref","unstructured":"Henriksson JT, De Paiva CS, Farley W, Pflugfelder SC, Burns AR, Bergmanson JP. Morphologic alterations of the palpebral conjunctival epithelium in a dry eye model. Cornea. 2013; 32: 483\u2013490.","DOI":"10.1097\/ICO.0b013e318265682c"},{"key":"i1552-5783-59-7-3088-b25","doi-asserted-by":"crossref","unstructured":"De Paiva CS, Volpe EA, Gandhi NB, et al. Disruption of TGF-beta signaling improves ocular surface epithelial disease in experimental autoimmune keratoconjunctivitis sicca. PLoS One. 2011; 6: e29017.","DOI":"10.1371\/journal.pone.0029017"},{"key":"i1552-5783-59-7-3088-b26","doi-asserted-by":"crossref","unstructured":"Barabino S, Shen L, Chen L, Rashid S, Rolando M, Dana MR. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005; 46: 2766\u20132771.","DOI":"10.1167\/iovs.04-1326"},{"key":"i1552-5783-59-7-3088-b27","unstructured":"Lin Z, Liu X, Zhou T, et al. A mouse dry eye model induced by topical administration of benzalkonium chloride. Mol Vis. 2011; 17: 257\u2013264."},{"key":"i1552-5783-59-7-3088-b28","doi-asserted-by":"crossref","unstructured":"Rios JD, Horikawa Y, Chen LL, et al. Age-dependent alterations in mouse exorbital lacrimal gland structure, innervation and secretory response. Exp Eye Res. 2005; 80: 477\u2013491.","DOI":"10.1016\/j.exer.2004.10.012"},{"key":"i1552-5783-59-7-3088-b29","doi-asserted-by":"crossref","unstructured":"Obata H, Yamamoto S, Horiuchi H, Machinami R. Histopathologic study of human lacrimal gland. Statistical analysis with special reference to aging. Ophthalmology. 1995; 102: 678\u2013686.","DOI":"10.1016\/S0161-6420(95)30971-2"},{"key":"i1552-5783-59-7-3088-b30","doi-asserted-by":"crossref","unstructured":"Mor M, Shalev A, Dror S, et al. INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats. J Pharmacol Exp Ther. 2013; 344: 59\u201367.","DOI":"10.1124\/jpet.112.200873"},{"key":"i1552-5783-59-7-3088-b31","doi-asserted-by":"crossref","unstructured":"Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013; 11: 246\u2013258.","DOI":"10.1016\/j.jtos.2013.07.003"},{"key":"i1552-5783-59-7-3088-b32","doi-asserted-by":"crossref","unstructured":"Zoukhri D. Effect of inflammation on lacrimal gland function. Exp Eye Res. 2006; 82: 885\u2013898.","DOI":"10.1016\/j.exer.2005.10.018"},{"key":"i1552-5783-59-7-3088-b33","doi-asserted-by":"crossref","unstructured":"Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest. 2005; 115: 35\u201343.","DOI":"10.1172\/JCI22656"}],"container-title":["Investigative Opthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?articleid=2685922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:30:54Z","timestamp":1791927054000},"score":1,"resource":{"primary":{"URL":"http:\/\/iovs.arvojournals.org\/article.aspx?doi=10.1167\/iovs.18-24432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.18-24432","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,19]]}}}